U.S. could control COVID by spring 2022 if more people get shots -Fauci
Send a link to a friend
[August 25, 2021]
By Susan Heavey and Carl O'Donnell
WASHINGTON (Reuters) -The United States
could get COVID-19 under control by early next year if vaccinations ramp
up, Dr. Anthony Fauci said on Tuesday, one day after Pfizer won fuller
FDA approval for its shot, with more potential approvals coming in the
weeks ahead.
Fauci, the nation's top infectious disease expert, said in multiple
television interviews and a White House press conference that full Food
and Drug Administration approval for the Pfizer-BioNTech vaccine paves
the way for more people to get inoculated https://tmsnrt.rs/3tUM8ta,
with potential approval for Moderna Inc's in the coming weeks and
authorization for younger children by autumn.
"I would like to appeal to the people in the country who are not
vaccinated to realize that we have the capability, among ourselves, to
essentially cut down the time frame to getting to the end of this
pandemic," Fauci, head of the National Institutes of Allergy and
Infectious Diseases, said during a Tuesday press conference.
"I think there's a reasonable chance" that Pfizer or Moderna could get
FDA clearance for children under 12 before the upcoming holiday season,
he told NBC News. "Hopefully by the mid-late fall and early winter."
U.S. officials during the Tuesday press briefing also urged private
employers and more state and local governments to require staff to get
vaccinated in a bid to drive up vaccination rates.
"Now is the time" for U.S. employers to start mandating vaccinations,
White House COVID coordinator Jeffrey Zients said, echoing remarks from
President Joe Biden on Monday.
Meanwhile, the White House is preparing to provide third "booster" doses
starting in mid-September to Americans who received their COVID-19
inoculation more than eight months ago. The plan depends upon a thumbs
up from the FDA and an advisory panel to the CDC.
"We want to make sure we stay ahead of the virus," Zients said, adding
that "the plan is pending the FDA conducting an independent evaluation
and outside experts... issuing a booster dose recommendation."
[to top of second column]
|
Top infectious disease expert Dr. Anthony Fauci responds to
accusations by Sen. Rand Paul (R-KY) as he testifies before the
Senate Health, Education, Labor, and Pensions Committee on Capitol
hill in Washington, D.C., U.S., July 20, 2021. J. Scott Applewhite/Pool
via REUTERS
Fauci added that healthcare providers should also
make more use of COVID-19 antibody treatments, including those from
Eli Lilly & Co, Regeneron Pharmaceuticals, and GlaxoSmithKline Plc/Vir
Biotechnology Inc. Such treatments can reduce hospitalizations and
deaths by as much as 85% if used early in infected people, he said.
The United States is battling another wave of cases https://tmsnrt.rs/2WkNEK5
due to the highly contagious Delta variant. Hospitalizations and
deaths are also rising, particularly in Florida, Mississippi,
Louisiana, Texas and other parts of the U.S. South.
The average number of deaths from COVID-19 has risen by 23% over the
previous seven-day period, Dr. Rochelle Walensky, director of the
U.S. Centers for Disease Control and Prevention, during a Tuesday
press call. The United States is now averaging 1,000 COVID deaths a
day and over 150,000 new cases, according to a Reuters tally.
U.S. health officials have also noted the number of inoculations has
also risen in recent weeks and say they hope Monday's FDA action
spurs more people get their first shots.
The U.S. military, along with several businesses and universities,
including CVS Health Corp, privately held Deloitte and at least one
college football team, have moved ahead with COVID vaccine mandates
since the FDA's announcement, which also buoyed Wall Street.
(Reporting by Susan Heavey and Carl O'Donnell; additional reporting
by Lisa Lambert; Editing by Dan Grebler and Lisa Shumaker)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |